AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Method of Preparing Multivalent Single Chain Antibodies (scFv)

Technology Benefits

This method surpasses previous methods of production, such as using polyvalent proteins and antibodies, which were limited by low throughput and high cost.

Technology Application

This method provides an efficient and controllable way to produce multivalent antibodies for the advancement of scFv against cancer.

Detailed Technology Description

Single chain fragments (scFv) derived from the small binding domain of parent monoclonal antibodies (MAb) offer pharmacokinetic advantages and target tumor cells more efficiently than MAb. However, methods for producing multivalent scFv have proven to be very challenging. UC Davis researchers have recently developed a novel method to construct divalent scFv through a small linker using 1,3-dipolar cycloaddition chemistry.

Supplementary Information

Patent Number: US20090234105A1
Application Number: US2008294227A
Inventor: Gervay-Hague, Jacquelyn | Du, Wenjun | Denardo, Sally | Natarajan, Arutselvan
Priority Date: 24 Mar 2006
Priority Number: US20090234105A1
Application Date: 23 Sep 2008
Publication Date: 17 Sep 2009
IPC Current: C07K001646 | A61P003500
US Class: 5303873
Assignee Applicant: The Regents of the University of California
Title: Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition
Usefulness: Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition
Summary: For treating breast and prostate cancer cells expressing mucin-1 (MUC-1) antigen (claimed).
Novelty: Covalently attaching two proteins to form a conjugate protein for treating breast cancer involves contacting first protein with alkyne moieties with second protein having linking group with terminal azide moiety, to form 1,2,3-triazole